Current studies have primarily focused on comparing the advantages and disadvantages of P-CAB and PPI drugs, with little comparison between different P-CAB drugs or between regimens with varying drug combinations and treatment durations. This study aims to evaluate the clinical effectiveness of vonoprazan-based H. pylori eradication therapy and compare it to that of conventional PPI based therapy in clinical practice.
Currently, there are numerous H. pylori eradication regimens, but opinions vary regarding the effectiveness of those based on P-CAB or PPI. Zhang et al. 4 concluded that the P-CAB-based triple regimen was superior to the PPI-based regimen, whereas Du et al.5 suggested that a vonoprazan and amoxicillin duo regimen may be the preferred first-line option for H. pylori eradication in clinical practice. However, due to limited evidence, the efficacy of various H. pylori eradication regimens using tegoprazan or vonoprazan could not be compared. Current studies have primarily focused on comparing the advantages and disadvantages of P-CAB and PPI drugs, with little comparison between different P-CAB drugs or between regimens with varying drug combinations and treatment durations. This study aims to evaluate the clinical effectiveness of vonoprazan-based H. pylori eradication therapy and compare it to that of conventional PPI based therapy in clinical practice. Objective: To compare the efficacy of vonoprazan-based H. pylori eradication therapy with conventional proton pump inhibitors based therapy.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
128
Clarithromycin 500 mg orally twice daily for 14 days
Omeprazole 40 mg orally twice daily for 14 days, then 40 mg once daily for 4 weeks
Omeprazole 40 mg orally twice daily for 14 days, then 40 mg once daily for 4 weeks
Rehman Medical Institue
Peshawar, K, Pakistan
H. pylori Eradication Rate
Proportion of participants with successful eradication of Helicobacter pylori infection, confirmed by a negative stool antigen test.
Time frame: 4-6 weeks after completion of therapy
Incidence of Adverse Events
Number and type of treatment-related adverse effects (e.g., nausea, diarrhea, headache, abdominal discomfort) reported by participants during or after therapy
Time frame: During the 6-week treatment and follow-up period
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Clarithromycin 500 mg orally twice daily for 14 days
Amoxicillin 1 g orally twice daily for 14 days
Vonoprazan 20 mg orally twice daily for 14 days, then 20 mg once daily for 4 weeks
Levofloxacin 500 mg orally once daily for 14 days
Amoxicillin 1 g orally twice daily for 14 days
Omeprazole 40 mg orally twice daily for 14 days, then 40 mg once daily for 4 weeks
Levofloxacin 500 mg orally once daily for 14 days
Amoxicillin 1 g orally twice daily for 14 days
Vonoprazan 20 mg orally twice daily for 14 days, then 20 mg once daily for 4 weeks